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Clinics 
Age and sex 
76 years old female patient. 
Previous history 
Preleukemia. Low risk myelodysplastic syndrome 
(refractory anemia) diagnosed 32 months before 
(December, 2009).No previous malignancy, no inborn 
condition of note.  
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged lymph 
nodes, no central nervous system involvement.  
Blood 
WBC: 2.7X 109/l 
HB: 8.5g/dl 
Platelets: 146 X 109/l 
Blasts: 0% 
Bone marrow: 5% (Global normocellularity, with 
erythroid and megakaryocytic hyperplasia and 
megakaryocytic dysplasia (no-lobated megakaryocytes 
suggestive of 5q- Syndrome), less than 5% of 




Myelodysplastic Syndrome - Refractory anemia with 
ring sideroblasts (FAB classification). 
Diagnosis 
Myelodysplastic Syndrome - Refractory citopenia with 
multilineage dysplasia and ringed sideroblasts (WHO 
classification). 
Survival 
Date of diagnosis: 08-2012 
Treatment: Erythropoietin 
Complete remission: no  
Treatment related death: no  
Relapse: no  
Status: Alive  
Last follow up: 09-2012 
Survival: 1 month from the cytogenetic abnormality 
detection, 30 months from the MDS diagnosis.months 
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Partial G-banded karyotypes showing the del(5)(q13q31) and the t(X;20)(q13;q13.3) 
 
Karyotype 
Sample: Bone marrow 






Karyotype at Relapse 
not done 
Comments 
The band Xq13 is frequently involved in 
rearrangements seen in hematological malignancy. The 
structural rearrangement idic(X)(q13) is associate with 
the myelodysplastic syndrome with ringed sideroblasts 
and this region is difficult for mapping because is rich 
in complex repeats with subregional inversions and 
high concentration of LINE repeats (boosters of X-
inactivation). The chromosome 20q interstitial 
deletions are well established nonrandom abnormalities 
in myeloid disorders, particularly in polycythemia vera 
and myelodysplasia. Very few cases of translocations 
involving chromosome 20 have been reported in 
hematological malignancy. The band 20q13 is rich in 
cancer genes and translocation involving this region 
has been reported in cases of acute myeloid leukemia. 
One study shows that breakpoints of X chromosomes 
associated with myelodysplasia were located in a 
region of 450 kb next to the gene XIST (Xq13). 
Another study demonstrated that a critical event in 
myelodysplasia is loss of tumor suppressor genes 
present on the long arm of chromosome 20. This 
suppression can occur when a potential cryptic deletion 
is associated with a translocation. This phenomenon 
generates a second mechanism causing inactivation of 
the X chromosome and derivative 20 resulting loss of 
function of tumor suppressor genes.  
Seven cases of t(X;20)(q13;q13) were described in 
literature; all affecting women over the age of 57 with 
myeloid disorders.  
We report the detection, by conventional cytogenetic 
methods, the t(X;20)(q13;q13.3) in one female patient 
with myelodysplastic syndrome subtype Refractory 
citopenia with multilineage dysplasia and ringed 
sideroblasts (classification WHO).  
Although this translocation was described as a primary 
clonal chromosome abnormality, in this case the 
t(X;20) seems to be a secondary chromosome 
abnormality following a deletion 5q. 
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